Elite Pharmaceuticals Inc (ELTP)

[Couch]

NEWBIES take a look at #3 - its the ADT ZEITGEIST ELTP is in the MIDST of. Elite doesn't have to be the best or first regardless of whether it is. A TON of CASH will be made by those BUYING NOW $$$$$$$$$

Let me clear up one piece BS misinformation I continue to hear.

1) Nasrat became CEO at .068 and so the PPS has increased 4 to 5 fold while the share count hasn't even doubled since he became CEO. Don't believe me check the SEC Quarterly filings. They will back me up. Notice the lack of question mark.

2) NOW in terms of ELI 200 getting approved- you don't hire this man without knowing what your chances are. Eli 200 is coming and not a damn thing anybody is going to do about it. Notice his experience colored in red. The man is a force and NO OTHER ADT company has anybody like him -Period and a FACT.

http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=81371&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0
Quote:
Mr. Pfeifer brings with him more than 45 years of regulatory and trade experience, most recently having served as a law partner at King & Spalding in Washington DC and prior to that as a law partner at the Burditt, Bowles & Radzius. Among his many accomplishments, he was a major participant in the development of the Drug Price Competition and Patent Term Restoration Act of 1984, and provided strategic counseling to companies affected by that statue. In addition, he has provided regulatory advice and representation on a wide variety of FDA, FTC, and DEA regulated activities, including product approval, advertising, promotion, and compliance issues.

Prior to working at Burditt, Bowles and Radzius, Mr. Pfeifer served for a year in the General Counsel's office of the Federal Trade Commission, where he represented the FTC in Federal Court to enjoin violations of the Federal Trade Commission Act, and served ten years in the Chief Counsel's Office at the FDA as Associated Chief Counsel for Enforcement, Associate Chief Counsel for Drugs and Deputy Chief Counsel for Regulations and Hearings. During his tenure at the FDA, he was the FDA's lead litigator and Appellate Court advocate, and he briefed the FDA's cases before the Supreme Court. Mr. Pfeifer is a graduate of Brown University and the Georgetown University Law Center.


3) 4-REASONS-ELTP-is-in-the-Midst-of-the-Perfect-Storm:-A-GREAT-BUY-NOW:


1) Elite Announces U.S. FDA Priority Review Designation For SequestOx™ NDA


http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=80708&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

The FDA has set a target action date under the Prescription Drug User Fee Act ("PDUFA") of July 14, 2016.

######################################################################

Quote:
2) Bowing to pressure, FDA to reform painkiller approval process


http://www.reuters.com/article/us-fda-califf-idUSKCN0VD2MJ

Bowing to pressure from lawmakers, Dr. Robert Califf, President Barack Obama's nominee to lead the Food and Drug Administration, said on Thursday the agency would reform its process for approving opioid painkillers.

The FDA said in its announcement it would develop additional safety information for immediate-release opioid painkillers; strengthen the requirement for drugmakers to produce information after a drug reaches the market; and expand access to abuse-deterrent opioid drug formulations.

####################################################################

Quote:
3) MAJORITY OF PUBLIC SUPPORTS REQUIRING ABUSE DETERRENT FORMULATIONS IN MOST-ABUSED PRESCRIPTION DRUGS


http://abusedeterrent.org/news/MAJORITY-OF-PUBLIC-SUPPORTS-REQUIRING-ABUSE-DETERRENT-FORMULATIONS0aIN-MOST-ABUSED-PRESCRIPTION-DRUGS0a.aspx#.VuvYJXg39FJ

McLean, Virginia. A new national survey reports 65% of adults in the U.S. believe the Food & Drug Administration should require pharmaceutical manufacturers to include an abuse deterrent formulation (ADF) in all of their most abused drugs, both name-brand and generic.

With the United States facing its worst prescription drug abuse problem ever, the emerging new technology of ADF’s helps prevent the crushing, snorting and injecting of prescription painkillers when abusers are seeking an immediate high. The FDA has approved labels for 5 Schedule II drugs with abuse deterrent properties, and 9 states have passed legislation related to ADF prescribing, but with no national mandate in place, it is easy for abusers to switch to prescription drugs without an abuse deterrent formulation.

Two-thirds of U.S. adults would also support legislation introduced in the U.S. Congress to mandate that pharmaceutical companies place abuse deterrent formulations in their products within the next four years.

######################################################################

Quote:
4) Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey


http://www.fiercedrugdelivery.com/story/physicians-call-novel-abuse-deterrent-opioid-agonistantagonist-formulations/2015-11-09

A survey of more than 200 physicians found that 31% think opioid antagonists is the abuse-deterrent formulation that is most needed to combat the opioid abuse epidemic--an issue that's been implicated in the startling rise of the death rate of middle-aged white Americans without a college degree.

What type of abuse- deterrent formulation is most needed?

Number (out of 214 respondents)

Opioid antagonist/agonist combination 66 (31%)
Physical or chemical barrier 48 (22%)
Novel delivery system 34 (16%)
Aversion 33 (15%)
Prodrug 14 (7%)
Other or combination of above 19 (9%)
FierceDrugDelivery supplied the question to Quantia MD, the provider of a physician engagement platform that counts one-third of U.S. doctors as its members.

Out of 214 physicians, 66 said opioid antagonists/agonists are the most needed formulation. Opioid antagonists are substances that interfere with the euphoria associated with drug abuse. The deterrents would generally be released and activated only if the product is manipulated, such as during crushing or snorting.